Long-term treatment of GERD: an interview with Chris Rowland, CEO, Medigus

insights from industryChris Rowland, CEO, Medigus

Currently, what is the leading laparoscopic method for the long-term treatment of gastroesophageal reflux disease (GERD)?

Currently, the leading laparoscopic method for the long-term treatment of GERD is the Nissen fundoplication — a surgical procedure in which the fundus (the upper part of the stomach) is wrapped (plicated) around the lower esophageal sphincter and typically sewn into place. This procedure is intended to reinforce the lower esophageal sphincter (LES) to help prevent stomach acids from backing into the esophagus and causing irritation.

What are the main drawbacks of this method?

The main drawback of this method is that the procedure requires incisions, making it likely that patients will experience additional discomfort and have a longer recovery time. This is both inconvenient for patients and more costly for healthcare institutions.

Why is there an existing gap in GERD treatment between drug therapy and invasive laparoscopic procedures?

To control reflux symptoms, many people take acid-controlling medications such as Proton Pump Inhibitors, or PPIs.  The FDA, however, has issued warnings over the frequent or long-term continued use of PPIs, citing concerns that overuse can lead to osteoporosis, interference with nutrient absorption or other digestive complications.

However, many people choose not to undergo surgical fundoplication procedures, because they feel it is too invasive and rather stick with medication.  For people who fall within this treatment gap, MUSE offers a more patient-friendly, incisionless alternative to laparoscopic surgery, for the long-term treatment of GERD.

Please can you give a brief overview of the Medigus Ultrasonic Surgical Endostapler, or MUSE?

The MUSE system is an intuitive, endoscopic platform for the long-term, possibly permanent, treatment of GERD.  It is equipped with the latest technological advancements in microvisualization, ultrasound and surgical stapling, thereby allowing a single physician or surgeon to perform anterior partial fundoplication more easily than with leading laparoscopic methods.

Its platform consists of a single use flexible surgical endostapler, equipped with a proprietary miniature camera, an ultrasonic sight and a range finder, and includes a handle with controls, an 80cm flexible shaft, a 5cm rigid section holding a cartridge with 5 standard 4.8mm titanium surgical staples, a ratchet controlled one-way articulating section, and a distal tip.

The MUSE endostapler is progressed into the stomach through an overtube and retroflexed under direct video guidance.  After identifying an ideal stapling location, the stapler is gently pulled back to place the staple cartridge in the lower esophagus approximately 3cm above the gastroesophageal junction.  The procedure typically delivers about five staples to effectively reinforce the LES.

The device’s video camera offers direct visualization during insertion and staple site selection, and ultrasound to determine when a proper stapling gap is achieved.

At what stage of development is MUSE at?

The MUSE system is FDA cleared and CE marked for the treatment of GERD and is already in use by leading gastroenterologists and GI surgeons throughout the United States and Europe.

Renowned gastroenterologist, Professor Pier Alberto Testoni, Director of Gastroenterology and Digestive Endoscopy IRCCS at San Raffaele Hospital in Milan, recently completed three MUSE procedures. What feedback did he give?

He was happy to report that all patients were released from the hospital within two days following their procedure, and have reported no complications.

In what ways do you think MUSE will improve GERD-related quality of life for patients?

Those who suffer from persistent GERD may find that, following treatment with MUSE, they have significantly reduced, or perhaps altogether eliminated the use of PPIs, which could contribute to an improvement in GERD-related quality of life.

In a recent study, six weeks following treatment with the MUSE system, 92% of patients had stopped the use of daily GERD medications and had normalized quality of life scores, while 69% had eliminated use of GERD medications altogether.  Average esophageal acid content was also significantly reduced following the procedure.

After 5 years, over 90% of study participants maintained their normalized quality of life measures and approximately 77% had ceased taking daily GERD medications.

Without having to adhere to potentially restrictive dietary or medication regimens, people may be able to enjoy more physical activities, greater freedom in food choices or even simply feel more comfortable without suffering the troublesome symptoms of reflux.

How do you hope to improve MUSE going forwards?

Our focus is currently on rolling out across the United States and Europe.

What do you think the future holds for GERD treatments and how do Medigus plan to add to it?

I think the GERD market will become stratified and offer the patient several less invasive options on the path between PPT and LNF.  Medigus plans to focus on an existing and effective procedure (lap fundoplication) only in a new less invasive approach (trans-orifice).

Where can readers find more information?

You can find more information about the MUSE system from www.medigus.com.  The site features useful information for patients as well as physicians.

About Chris Rowland

Chris is CEO of Medigus and serves as a member of the board of directors.

Earlier, Chris was President and CEO of NeoTract, Inc. From 2006 to 2009 he served as President Americas and was a member of the Executive Committee for Given Imaging (NASDAQ: GIVN – www.givenimaging.com).

Prior to his position at Given Imaging, Chris worked for the Boston Scientific Corporation (www.bsci.com) for seventeen years in many divisions in positions of increasing responsibility from Sales, Product Development, Marketing, Business Development and General Management. Chris has also held a position at Xerox Corporation.

During his career, Chris has received over 25 Patents for a variety of minimally invasive medical devices. Chris has a B. Sc. in Marketing from Southern Illinois University and has completed the Executive Leadership Program at Harvard Business School and the Executive Management Program at Columbia Business School.

April Cashin-Garbutt

Written by

April Cashin-Garbutt

April graduated with a first-class honours degree in Natural Sciences from Pembroke College, University of Cambridge. During her time as Editor-in-Chief, News-Medical (2012-2017), she kickstarted the content production process and helped to grow the website readership to over 60 million visitors per year. Through interviewing global thought leaders in medicine and life sciences, including Nobel laureates, April developed a passion for neuroscience and now works at the Sainsbury Wellcome Centre for Neural Circuits and Behaviour, located within UCL.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Cashin-Garbutt, April. (2023, April 07). Long-term treatment of GERD: an interview with Chris Rowland, CEO, Medigus. News-Medical. Retrieved on July 22, 2024 from https://www.news-medical.net/news/20150518/Long-term-treatment-of-GERD-an-interview-with-Chris-Rowland-CEO-Medigus.aspx.

  • MLA

    Cashin-Garbutt, April. "Long-term treatment of GERD: an interview with Chris Rowland, CEO, Medigus". News-Medical. 22 July 2024. <https://www.news-medical.net/news/20150518/Long-term-treatment-of-GERD-an-interview-with-Chris-Rowland-CEO-Medigus.aspx>.

  • Chicago

    Cashin-Garbutt, April. "Long-term treatment of GERD: an interview with Chris Rowland, CEO, Medigus". News-Medical. https://www.news-medical.net/news/20150518/Long-term-treatment-of-GERD-an-interview-with-Chris-Rowland-CEO-Medigus.aspx. (accessed July 22, 2024).

  • Harvard

    Cashin-Garbutt, April. 2023. Long-term treatment of GERD: an interview with Chris Rowland, CEO, Medigus. News-Medical, viewed 22 July 2024, https://www.news-medical.net/news/20150518/Long-term-treatment-of-GERD-an-interview-with-Chris-Rowland-CEO-Medigus.aspx.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Americans' ability to afford healthcare hits new low in 2024